Navigation Links
Virginia Faith Leaders Call on Senators Webb & Warner to Cosponsor Legislation to Protect Kids from Tobacco
Date:10/9/2007

said Dr. Imad Damaj, President, Virginia Muslim Coalition. "It is critical to our communities and our public health to stop the marketing of tobacco products to our children. Congress needs to authorize the FDA to put an end to this marketing and help us protect our children from this deadly addiction."

Recent reports by the President's Cancer Panel and Institute of Medicine (IOM) concluded that in order for the United States to dramatically reduce tobacco use as a significant public health problem, it is essential to provide FDA authority over tobacco products. As the IOM concluded, "The time has come for Congress to exercise its acknowledged authority to regulate the production, marketing and distribution of tobacco products."

"The tobacco companies get away with their harmful practices because no government agency currently has any real authority over how tobacco products are manufactured or marketed," said Rabbi Ben Romer of Richmond's Congregation Or Ami. "This year, Congress has an opportunity to do something truly important to improve the health of America's families."

Identical, bipartisan bills to grant the FDA authority over tobacco have been introduced in the Senate and House of Representatives. Demonstrating strong, bipartisan support, the legislation has 55 Senate sponsors and 200 House sponsors. The Senate Health, Education, Labor and Pensions Committee passed the legislation on August 1.

This legislation has the support of every major national public health organization and more than 500 public health, faith and other organizations across the country (see list at: http://www.tobaccofreekids.org/reports/fda/organizations.pdf ), as well as the strong support of the American people. According to a recent national poll, 70 percent of voters support Congress passing the legislation and 72 percent believe passage of the legislation would be
'/>"/>

SOURCE Faith United Against Tobacco
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Once a Lawn Mower, a Self-made Billionaire Makes a Lasting Gift to Virginia Tech
2. West Virginia Organizes a Program to Fight Obesity
3. Indians Add to Rich Diversity of Virginia Tech
4. Virginia Tech. Shooter -Human Rights or Innocent Lives
5. Virginia Tech Shooters Mental Health Records No More Secret
6. Fire Ants are Emerging Nuisance for Virginians
7. Australian Devises Online Game Based on Virginia Tech Shootout
8. Pain Doctor in Virginia Sentenced to Five Years Imprisonment
9. Five Killed by Methane Gas on Virginia Farm
10. Link between Faith, Health and Healing
11. Prayer and Faith Helps Parents Endure Their Child’s Deat
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8Handwriting Skills May Lag in Kids With Autism 61014 1Handwriting Skills May Lag in Kids With Autism 61014 2Doctors Spending More Time Now With Patients 61011 1Doctors Spending More Time Now With Patients 61011 2Doctors Spending More Time Now With Patients 61011 3Fitness com au Poll Finds 80 25 Blame Parents For Our Overweight Kids 61009 1Fitness com au Poll Finds 80 25 Blame Parents For Our Overweight Kids 61009 2